BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/6/2019 8:51:28 AM | Browse: 829 | Download: 1393
 |
Received |
|
2018-12-19 06:35 |
|
Peer-Review Started |
|
2018-12-20 03:05 |
|
To Make the First Decision |
|
2019-01-07 00:25 |
|
Return for Revision |
|
2019-01-08 07:08 |
|
Revised |
|
2019-01-12 01:06 |
|
Second Decision |
|
2019-01-29 06:30 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-01-30 02:20 |
|
Articles in Press |
|
2019-01-30 02:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-03-05 07:56 |
|
Publish the Manuscript Online |
|
2019-03-06 08:51 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Case Report |
| Article Title |
Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mie Mie Thinn, Chung-Tzu Hsueh and Chung-Tsen Hsueh |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Chung-Tsen Hsueh, MD, PhD, Professor, Division of Medical Oncology and Hematology, Department of Medicine, Loma Linda University, 11175 Campus Street, CSP 11015, Loma Linda, CA 92357, United States. chsueh@llu.edu |
| Key Words |
Squamous cell carcinoma of head and neck; Epidermal growth factor receptor; Erlotinib; Complete response; Skin rash; Tyrosine kinase inhibitor; Case report |
| Core Tip |
We present a patient with recurrent/metastatic squamous cell carcinoma of head and neck who had durable complete response after completion of 6-mo erlotinib treatment. Patient experienced severe skin rash and diarrhea toxicities from erlotinib. The severity of these adverse effects has been shown to be predictors of treatment response from inhibitors of epidermal growth factor receptor. |
| Publish Date |
2019-03-06 08:51 |
| Citation |
Thin MM, Hsueh CT, Hsueh CT. Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report. World J Clin Cases 2019; 7(5): 616-622 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i5/616.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i5.616 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
